Skip to main content

 

 

Submissions

Allergy & Anaphylaxis Australia (A&AA) is a charitable, non-profit organisation established in 1993 to support and assist those affected by allergy and anaphylaxis. A&AA is dedicated to assisting individuals, their caregivers and all in the community in the management of allergic conditions including food allergy. A&AA’s aim is to enable individuals and their families to enjoy an optimal quality of life whilst minimising risk to their health and wellbeing. A&AA strives to raise awareness of allergy in the community and provides evidence-based information, resources and services to support children and adults living with allergic disease including food allergy. 

Select a link below to access A&AA's submission.

Submission: a new PBS listing for Jext® Jnr and Jext® - 28 May 2024

Allergy & Anaphylaxis Australia (A&AA), the Australasian Society of Clinical Immunology and Allergy (ASCIA) and the National Allergy Council welcome the opportunity to lodge our comments regarding the submission for a new PBS listing for Jext® Jnr and Jext® which is on the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting agenda. Jext®...

Continue reading

Submission: Codex Committee on Food Labelling - Electronic Working Group on Allergen Labelling - March 2024

1st Consultation Paper – March 2024:  A&AA provided a response to the Codex eWG Allergen Labelling online – forum. Question 1: Do you agree to removing the bracketed text [or substance or processing aid] from the proposed definition for ‘food allergen as shown below? “Food allergen” means a food or ingredient [or substance or processing aid] used in...

Continue reading

Submission: Codex Committee on Food Labelling - Electronic Working Group on Allergen Labelling - Oct 2022

Second Consultation Paper - October 2022:  The EWG are asked to provide comments on the proposed draft revisions to the GSLPF as discussed in Part 1 of the consultation paper. This includes providing comments on the proposed definitions at Section 2 of Part 1. See PDF for full submission.  AAA review Codex Pal Nov2022217.61 KB

Continue reading

Submission: Draft Guidelines on the use of Technology to Provide Food Information in Food Labelling - 12 April 2024

Allergy & Anaphylaxis Australia (A&AA) has responded to the questions in the EWG 2nd Consultation Request. 1. Do you support the proposed revisions to Section 7.3? Please explain 2. Do you support the proposed revisions to Section 7.5? Please explain. 3. Do you support the re-introduction of the text in Section 5.2 for the reasons provided? 4. Please...

Continue reading

Submission: Codex Committee on Food Labelling – Information on emerging issues/future work - 25 March 2024

Allergy & Anaphylaxis Australia provided comments on CL 2024/24-FL – Information on emerging issues/future work and included the previous feedback to CL 2022/70-FL that was relevant to this submission. Allergy & Anaphylaxis Australia (A&AA) provided feedback in response to CL 2022/70-FL on 29 November 2022 that we have attached as we believe the issues...

Continue reading

Submission: Codex Request for comments on the revised draft approach and criteria for evaluation and prioritization of the work of Codex Committee for Food Labelling (CCFL) - 18 March 2024

Allergy & Anaphylaxis Australia provided comments on the criteria for evaluation and prioritization of the work of CCFL. A&AA supports the changes, but we have feedback on point 11: 11. The proposed work should be assessed against the criteria as per the ratings given for each criterion. New work proposals will ultimately be prioritized as per the overall...

Continue reading

Submission: Codex request for information on the Labelling of Alcoholic Beverages - 1 March 2024

Allergy & Anaphylaxis Australia provided responded to the questionnaire from the Codex Committee regarding the Labelling of Alcoholic Beverages 1. Mandatory labelling requirements - A&AA supports the mandatory labelling requirements for ingredients, including common food allergens, on all alcoholic beverages. We do not agree that there should be an exemption...

Continue reading

Submission to change to PBS listing of MEPOLIZUMAB Nucala® for uncontrolled severe asthma 30/01/2024

Please find below the joint submission from Allergy & Anaphylaxis Australia (A&AA) and the National Allergy Council to the Pharmaceutical Benefits Advisory Committee (PBAC) on changes requested by GlaxoSmithKline Australia Pty Ltd to the Pharmaceutical Benefits Scheme listing of mepolizumab (Nucala®) for uncontrolled severe asthma. We support the requested...

Continue reading

Submission to the PBAC on PBS listing of Neocate® Syneo - Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids 29/01/2024

AMINO ACID FORMULA SUPPLEMENTED WITH PREBIOTICS, PROBIOTICS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS - Neocate® Syneo: Cows' milk protein enteropathy; Severe cows' milk protein enteropathy with failure to thrive; Combined intolerance to cows' milk protein, soy protein and protein hydrolysate formulae; Proven combined immunoglobulin E (IgE) mediated allergy to...

Continue reading

Submission to PBAC on PBS listing of LEBRIKIZUMAB (EBGLYSS®) for severe atopic dermatitis (eczema) 29/01/2024

Please find below the joint submission from Allergy & Anaphylaxis Australia (A&AA) and the National Allergy Council to the Pharmaceutical Benefits Advisory Committee (PBAC) on the Pharmaceutical Benefits Scheme listing of Lebrikizumab (Ebglyss®) for the treatment of patients aged 12 years or older with severe atopic dermatitis (AD), affecting the whole...

Continue reading

Submission to PBAC on PBS listing of Dupilumab (Dupixent®) for severe uncontrolled asthma 29/01/2024

The National Allergy Council and Allergy & Anaphylaxis Australia (A&AA) both support the submission from Sanofi-Aventis to request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) Pharmaceutical Benefits Scheme (PBS) listing of dupilumab (Dupixent®) for the treatment of uncontrolled severe asthma in patients aged 6 to 11 years. The...

Continue reading

Australian medicine labelling rules – Targeted consultation on priorities for future improvements to TGO 91 and TGO 92 - 7 September 2023

Do we need to update more medicine labelling rules in the short term to support medicine safety before we conduct a broader review? Yes, Allergy & Anaphylaxis Australia (A&AA) believes that an update is required in the short term to the ‘’Declaration of Substances’’, with respect to the food allergens that must be declared. It is vital that information...

Continue reading

PROPOSED DRAFT REVISION OF THE GENERAL STANDARD FOR THE LABELLING OF PRE-PACKAGED FOODS (CXS 1-1985) 4 September 2023

PROVISIONS RELEVANT TO ALLERGEN LABELLING (FOR ADOPTION AT STEP 5)  Allergy & Anaphylaxis Australia (A&AA) does not support the proposed Draft Revision on the General Standard for the Labelling of Pre-Packaged Foods (CXS 1-1985): Provisions relevant to Allergen Labelling for adoption at Step 5. A&AA has several concerns that we needed to...

Continue reading

PROPOSED DRAFT GUIDELINES ON THE PROVISION OF FOOD INFORMATION FOR PRE-PACKAGED FOODS - 4 September 2023

OFFERED VIA E-COMMERCE (FOR ADOPTION AT STEP 5) Allergy & Anaphylaxis Australia (A&AA) supports the proposed Draft Guidelines on the Provision of Food Information for Prepackaged foods offered via E-Commerce for adoption at Step 5. A&AA has one point that we believe needs to be considered. The definition of ‘consumer’, referred to in the Purpose...

Continue reading

PROPOSED DRAFT GUIDELINES ON THE USE OF TECHNOLOGY TO PROVIDE FOOD INFORMATION - 4 September 2023 (2)

IN FOOD LABELLING (FOR ADOPTION AT STEP 5)  Allergy & Anaphylaxis Australia (A&AA) supports the proposed Draft Guidelines on the Use of Technology to provide Food Information in Food Labelling for adoption at Step 5. However, we did have two issues that we feel need to be considered: The definition of consumer. In the Purpose statement...

Continue reading

P1028 – Infant formula | Special Medical Purpose Products for Infants (SMPPi) 7 July 2023

A&AA (Allergy & Anaphylaxis Australia) supports the proposal by FSANZ (Food Standards Australia New Zealand) to create a new category of infant formula that has been developed for a specific disease, disorder, or medical condition within Standard 2.9.1. A&AA supports the proposed sale restriction of a SMPPi (Special Medical Purpose Products for Infants)....

Continue reading

Ongoing PBS listing of Dupilumab for treatment of chronic severe atopic dermatitis - 15 May 2023

This submission from Allergy & Anaphylaxis Australia (A&AA) to the Pharmaceutical Benefits Advisory Committee concerns the ongoing Pharmaceutical Benefits Scheme listing of Dupilumab (Dupixent®) for the treatment of chronic severe atopic dermatitis in people aged 12 years and over. A&AA is grateful for the opportunity to forward a submission expressing...

Continue reading

Submission concerning Jorveza® for EoE change to current PBS listing - 23 Jan 2023

Submission from Allergy & Anaphylaxis Australia (A&AA): We welcome the opportunity to lodge our comments in support of the submission for Jorveza® (Budesonide) which is on the March 2023 Pharmaceutical Benefits Advisory Committee (PBAC) meeting agenda. Jorveza® was PBS listed in May 2022 specifically for the treatment of EoE. This application is for...

Continue reading

Submission on change to PBS listing Mepolizumab Injection - 15 Sep 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Change to PBS listing Mepolizumab Injection (Nucala®) to include use for people diagnosed with chronic rhinosinusitis with nasal polyps. A&AA supports the PBS listing of Mepolizumab so that people with chronic rhinosinusitis with nasal polyps can, together with their treating medical...

Continue reading

Submission concerning Codex Committee on Food Labelling | Response - 8 July 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Codex Committee on Food Labelling | Electronic Working Group on Allergen Labelling.  A&AA provides response on 1st Consultation Paper on the Codex eWG Allergen Labelling online-forum. Response form A&AA to Codex Committee on Food Labelling 8 July 2022195.71 KB    ...

Continue reading

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.